pharmaceuticalhealthcareanalys

Cataract surgery devices are used during the surgical procedures to treat cataract, which is an eye disorder that causes clouding of the lens leading to defects in vision. Cataract is one of the most widespread disease causing blindness and it reduces vision ability. Cataract is often encountered to develop slowly and affect either one or both the eyes.

Click To Continue Reading on Cataract Surgery Devices Market

Although cataract does not interfere with the eyesight in the early stages, it interferes with vision and may lead to blindness over the course of time. The symptoms of cataract include blurry vision, trouble with bright lights, faded colors, and trouble seeing in the night. Cataract surgery is the most commonly performed ophthalmic procedure and thus holds a great potential for the growth of cataract surgery devices market.

According to the American Academy of Ophthalmology, over 24.4 million Americans of age 40 years and above were affected with cataract in 2014. The same report states that by the age of 75 years, almost half of the Americans have cataracts. According to the International Agency for the Prevention of Blindness (IAPB), approximately 285 million people are visually impaired worldwide out of which around 39 million are blind and about 246 million are suffering with low vision. The report suggests that cataract and glaucoma are the prime causes of blindness across the globe in 2015. However, 4 out of 5 blind or visually impaired cases are avoidable according to the Global Facts: Blindness and Visual Impairment. Increasing cataract surgeries are fueling the growth of global cataract surgery devices market.

On the basis of geography, the global cataract surgery devices market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is the highest contributor to the global cataract devices market, owing to the number of cataract surgeries occurring in the region. According to the American Academy of Ophthalmology 2014, approximately 2 million cataract surgery procedures were performed in the U.S., out of which 21% of patients were reported to have improved quality of vision in one eye while 36% patients reported improvement in vision quality of both the eyes after the cataract surgery.

Moreover, the global cataract surgery devices market is expected to flourish in the Asia Pacific due to cost cutting facility of the procedure as well as increasing incidence of cataract. For instance, the manual and suture less Small-Incision Cataract Surgery (SICS) is preferred in emerging economies such as China and India, where the cost of the surgical procedures are low as compared to other procedures.

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1197

Key Vendors:

Abbott Laboratories, Carl Zeiss Meditech AG, Bausch & Lomb, Inc., Allergen, Inc., Alcon, Inc., Opcon Corporation, Essilor International S.A., STAAR Surgical Company, and NIDEK Co., Ltd.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Visit our news Website: https://www.coherenttimes.org/

Spinal fusion devices are used to provide stability to spinal structure, which has lost stability due to a fracture, degenerative disorders of the spine, trauma, tumors, and deformity. Spinal cord injuries majorly happen due to various reasons such as a blocked blood supply, infections, injuries, and compression by a fractured bone or a tumor. Spinal fusion devices technology and mechanism of functioning has evolved over the years. Advanced plating systems offer improved stability and structural integrity. Spinal fusion devices have innovative locking mechanisms and screw systems, which can have self-drilling and self-tapping functions, made from modern manufacturing material such as titanium alloy, and single as well as double holes per vertebrae  through which the screw fixation is done.

Click To Continue Reading on Spinal Fusion Devices Market

In 2015, Aesculap Implant Systems, a division of B. BRAUN MELSUNGEN AG, launched Modulift Vertebral Body Replacement System (VBR). It is the latest generation of expandable cage technology. In 2017, Stryker’s Spine division launched Serrato pedicle screw, a unique dual-lead screw intended for use in the non-cervical spine. In 2016, Stryker launched Aero-C Cervical Stability System at the meeting of the American Academy of Orthopedic Surgeons in Orlando. Entry of these novel products in market is expected to support the growth of global spinal fusion devices market in near future.

Furthermore, frequent approvals of innovative products is also expected to drive market growth. For instance in 2018, Orthofix International N.V., received U S Food and Drug Administration 510(k) clearance of FORZA XP Expandable Spacer System. FORZA XP is designed to restore normal disc height in patients suffering from degenerative disc disease. In 2016, Orthofix International N.V. received US Food and Drug Administration 510(k) clearance for FORZA PTC (Peek Titanium Composite) Spacer System, and Wenzel Spine, Inc., received clearance from the U.S. Food and Drug Administration (FDA) to market VariLift-LX, an interbody fusion device for stand-alone use in the lumbar spine.

Factors responsible for spinal deformities include weight, diet, smoking, and other lifestyle factors. Early onset of degenerative spinal changes is attributed to the toxins in cigarette smoke damaging the cartilage of spine. According to World Health Organization (WHO), more than 1.1 billion people smoked tobacco in 2015 worldwide. According to a study published in SpineUniverse in 2017, disc herniation is the most common indication for spinal surgery, and around 75% of all spinal surgeries were performed for herniated disc. Increasing prevalence of spinal deformities due to unhealthy lifestyle and high chances of disc herniation are expected to drive growth of the spinal fusion devices market in near future.

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1211

Key Vendors:

Zimmer Biomet Holdings, Inc., Inc., Stryker Corporation, Inc., Exactech, Inc., Orthofix International N.V., Globus Medical, Inc., NuVasive, Inc., Medtronic Plc., Depuy Synthes, B. Braun Melsungen AG, Wenzel Spine, Inc., K2M Group Holdings, Inc., Centinel Spine, Inc., and Spineart Geneva SA.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Visit our news Website: https://www.coherenttimes.org/

Carcinoid syndrome is caused by secretion of certain harmful chemicals by carcinoid tumors. Carcinoid syndrome may occur due to infection or other related diseases, and medical or surgical treatments such as anesthesia, chemotherapy, embolization, and tumor debulking. The key symptoms of the syndrome include flushing of the skin and diarrhea, rapid heartbeat, and bronchoconstriction. If remained undiagnosed, it could lead to several complications such as weight loss, electrolyte imbalance, dehydrations, menopause, irritable bowel disease, and asthma.

Click To Continue Reading on Carcinoid Syndrome Diarrhea Treatment Market

For instance, in 2009, a study by Journal of Clinical Oncology, showed 4 to 5 out of every 100,000 people are diagnosed with a neuroendocrine tumor and over 100,000 people suffering from neuroendocrine tumor in the U.S., also most individual suffering from carcinoid are asymptomatic until the tumor is fully developed. To overcome the carcinoid crisis, treatment options may considered such as surgery, chemotherapy, targeted radionuclide therapy, radiofrequency ablation, and chemoembolization on the basis of patient-by-patient. Carcinoid syndrome being a rare condition, there are very few if any treatment options available. This in turn, creates a highly lucrative opportunities for market players.

In February 2017, Lexicon Pharmaceutical Inc., announced that the U.S. Food and Drug Administration (FDA) approved Xermelo (Telotristat etiprate) as the first and only orally administered therapy for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy (SSA) for adults. Xermelo mainly targets the overproduction of serotonin hormone inside mNET cells and reduces the frequency of carcinoid syndrome diarrhea. Furthermore, in 2017, Ipsen Biopharmaceutical, announced the U.S. Food and Drug Administration (FDA) approval for a supplemental indication of Somatuline Depot (lanreotide) Injection 120 mg for the treatment of carcinoid syndrome, to reduce the frequency of short-acting somatostatin analogue rescue therapy.

However, low awareness and certain side effects associated with this therapy are expected to hinder growth of the carcinoid syndrome diarrhea treatment market.

According to the National Organization for Rare Disorders (NORD), 2017, each year, only 27 individuals per million population are estimated to be diagnosed with carcinoid tumors in the U.S., amongst whom, only 10% individuals develop carcinoid syndrome. Moreover, it affects both males and females in equal number. Increasing prevalence of the disease is in turn, increasing demand for carcinoid syndrome diarrhea treatment devices. This in turn is expected to fuel growth of the carcinoid syndrome diarrhea treatment market.

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1216

Key Vendors:

Lexicon Pharmaceuticals, Inc., Novartis International AG (Sandoz), Pharmascience Inc., Omega Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Ipsen Biopharmaceuticals, Inc., Sirtex Medical Limited, and BTG International Ltd.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Visit our news Website: https://www.coherenttimes.org/

Therapeutic drug monitoring is a multidisciplinary practice of measuring drug amount in bloodstream to maintain its effective concentration. It is used to maximize efficacy of drug, avoid toxicity and adverse drug reactions (ADR), facilitate dose adjustment according patient requirement, and to identify therapeutic failure. It is used especially for drugs characterized by narrow therapeutic window, drugs that are highly protein bound and those in which the metabolite might be toxic. Physicians and hospitals use therapeutic drug monitoring to maximize the clinical benefits of the drug by minimizing the toxic side effects thereby improving the quality of life for the patients.

Click To Continue Reading on Therapeutic Drug Monitoring Market

North America holds the dominant position in therapeutic drug monitoring (TDM) market, owing to robust health care infrastructure, high awareness for treatment regime and increasing patient awareness regarding adverse drug reaction (ADR). According to 2013 survey by Medical Expenditure Panel published in Scientific American, 1 in 7 American adult consume Anti-Psychotic drug, a class of drugs which requires TDM. Stringent government regulations regarding safe medication practices especially with drugs having narrow therapeutic range would propel growth therapeutic drug monitoring. Moreover, increasing adoption of instruments such as monitors and analytic equipment, reagents, and diagnostics tools for drug monitoring is driving the growth of therapeutic drug monitoring market.

However, difficulty in reimbursement bars the widespread usage of TDM, as often the cost associated with TDM is high. Furthermore, insufficient infrastructure and skilled manpower is restraining the growth of the market in emerging economies.

Personalized medicine is driving the growth of therapeutic drug monitoring market, owing to increasing demand for better treatment outcome with minimum side effects from the medication. For instance, TDM is majorly used for anti-cancer drugs monitoring for which standard guidelines are recommended by many oncology Journal and associations, one of them being the European Journal of Oncology. Moreover, advanced treatment therapies such pharmacogenomics, gene testing, and proteomics is further expected to boost the growth of market. Increasing antimicrobial resistance is one of the key factor driving the growth of TDM market. According to WHO Factsheet 2017, antimicrobial resistance is one of the leading cause of death. For instance, according to WHO factsheet, around 4,80,000 multi-drug resistance TB cases were reported, which is creating an opportunity for physicians to optimize or monitor the drug therapies through TDM.

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1241

Key Vendors:

Roche Diagnostics, Thermo Fisher Scientific, Bio Rad Laboratories, Siemens Healthcare Diagnostics, Beckmann Coulter, and Abbott Diagnostics.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Visit our news Website: https://www.coherenttimes.org/

Hematopoietic stem cell transplantation is a procedure in which multipotent hematopoietic stem cells sourced from peripheral blood cells, bone marrow or umbilical cord blood are transplanted into a patient. Hematopoietic stem cell transplantation is commonly used in the treatment of lymphoma (Hodgkin, Non-Hodgkin), leukemia, multiple myeloma, thalassemia, sickle cell anemia, and osteoporosis. It includes two transplantation sources namely, autologous that uses stem cells from the patient’s own body and allogeneic that sources stem cells from a donor’s body.

Click To Continue Reading on Hematopoietic Stem Cell Transplantation Market

According to World Health Organization (WHO), over 50,000 hematopoietic stem cell transplantation procedures are carried out globally, every year and this number is expected to increase over the years.As per 2017 report by Leukemia and Lymphoma Society, the U.S. alone is expected to account for a prevalence of 8,16,834 and incidence of 80,500 for lymphoma. Increasing rate of incidence is in turn, expected to increase the demand for hematopoietic stem cell transplantation thus, propelling growth of the hematopoietic stem cell transplantation (HSCT) market. Increasing awareness about stem cell therapies among the population is also expected to propel growth of the hematopoietic stem cell transplantation market. As per survey by World Network for Blood and Marrow Transplantation (WBMN), around one million hematopoietic stem cell transplantation procedures were performed during 2006 to 2014, which indicates potential opportunities for market players.

However, high costs associated with hematopoietic stem cell transplantation procedures are expected to hinder growth of the market. Other factors such as difficulty in finding a donor for allogeneic transplantation, technological barriers (currently used culture technologies, point of care delivery, and lack of analytical assay), and side effects such as graft vs. host disease, are also expected to slow down growth of the hematopoietic stem cell transplantation market.

Increasing adoption of the growing trend of personalized medicine is expected to drive growth of the hematopoietic stem cells transplantation market. A collaborative research study on hematopoietic stem cell transplantation initiated by World Network for Blood and Marrow Transplantation (WBMN) in 2013 in the domain of promotion of access to hematopoietic stem cell transplantation, developed a donation guidance document, technical and scientific input on safety, and quality of HSCT as mentioned in annual report of the WBMN.

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1250

Key Vendors:

Pluristem Therapeutics Inc., CellGenix Technologie Transfer GmbH, Kite Pharma Inc., Regen Biopharma Inc., BiolineRx, Cynata Therapeutics, Lonza Group Ltd, Cesca Therapeutics Inc, TiGenix N.V., Escape Therapeutics Inc., Bluebird Bio, and Cellular Dynamics International.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Visit our news Website: https://www.coherenttimes.org/

Immuno-oncology involves use of patients’ immune system to fight against cancer. Immuno-oncology uses novel immunotherapies that boost the immune system of patients. These therapies target the immune system of the body instead of the tumors and enable the immune system to recognize and target cancer cells. Immuno-oncology does not affect the functioning of healthy cells as opposed to conventional therapies such as chemotherapy and radiation therapy. Long term response can be generated with the help of these therapies as they provide long-lasting memory to the immune system. Immune system adapts to the cancer over time and provides long term response to the cancer.

Click To Continue Reading on Immuno-oncology Drugs Market

Immuno-Oncology therapy work against a wide variety of cancer, which include non-small cell lung cancer, acute myeloid leukemia, lymphoma, multiple myeloma, breast cancer, and others. Immuno-oncology uses different types of cell-based immune therapies such as monoclonal antibodies, immune checkpoint inhibitors, cytokine based immunotherapy, cancer vaccines, and other therapies. Depending on the functioning of these therapies they are further classified into subtypes such as radiolabeled antibodies, chemo labeled antibodies, and bispecific monoclonal antibodies. Commercially available immune-oncology therapies include Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah.

Cancer treatment has become more refined with improved treatment success rate due to improved therapeutic outcomes. This has been possible due to deepened understanding of the disease pathophysiology, functioning of the tumor cells, and effective ways to tackle with the same. Immuno-oncology therapies exhibit lesser side effects as compared to conventional cancer therapies such as chemotherapy, radiation therapy, and others. Immuno-oncology therapy directly target the immune system of the body and does not harm healthy cells in the process, whereas, conventional therapies such as targeted therapy, chemotherapy, and radiation therapy affect cancerous as well as healthy cells extensively.

However, high cost of immuno-oncology therapies, which is unaffordable to low and middle class population is restraining growth of the market. For instance Keytruda (Pembrolizumab), a monoclonal antibody for the treatment of various types of cancer costs around US$ 2,250 for a vial of 50 mg.

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1271

Key Vendors:

Amgen, Inc. AstraZeneca Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., F. Hoffmann-La Roche AG, Johnson & Johnson, Novartis International AG, AbbVie, Inc., Pfizer Inc., Sanofi S.A., EMD Serono, Inc., Gilead Sciences Inc., Prometheus Therapeutics & Diagnostics, Aduro BioTech, Galena Biopharma, Bavarian Nordic, Celldex Therapeutics, ImmunoCellular Therapeutics, and Incyte.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Visit our news Website: https://www.coherenttimes.org/

Cardiac monitoring devices enable continual observation of patients with heart disorders. These devices are commonly used in emergency rooms and critical care units and primarily in arrhythmias to monitor the rate of heartbeats. Common types of cardiac monitoring devices include holter monitors, event monitors, loop monitors, and insertable cardiac monitors. The additional parameters monitored noninvasively by cardiac monitors include blood pressure, cardiac output, intravascular pressures, arterial blood oxygen saturation, and blood temperature.

Click To Continue Reading on Cardiac Monitoring Devices Market

Rise in incidence of cardiovascular diseases such as cardiac arrthymia, ischemic heart disease, and hypertension is expected to fuel growth of the cardiac monitoring devices market. According to World Health Organization (WHO), 2015, cardiovascular diseases was the leading cause of deaths accounting for 17.7 million deaths, globally. Furthermore, increasing applications of cardiac monitors in continuous monitoring for patients with severe electrolyte imbalances and for postoperative observation is expected to augment the market growth over the forecast period. Development of advance cardiac monitoring devices such as remote cardiac monitoring devices and wireless cardiac monitoring devices providing early detection is a major factor expected to boast the cardiac monitoring devices market growth over the forecast period.

For instance, ZywiePro, the next-generation cardiac remote monitoring solution launched in 2015, leverages mobile and cloud technology to facilitate detection of cardiovascular arrhythmias. ZywiePro enables physicians to provide more personalized and effective patient care by detailed diagnostic insight into the cardiovascular health of the patients. However, factors inhibiting the cardiac monitoring devices market include high cost of device and lack of knowledge about advance cardiac monitoring devices.

Advance cardiac monitoring devices enable physician to make accurate diagnosis and determine a treatment plan. For instance, the Reveal LINQ Insertable Cardiac Monitor manufactured by Medtronic, approved by FDA in 2014, is currently the smallest heart monitor in the market. It can diagnose the cause of infrequent, unexplained fainting spells better than conventional testing.

Regional segmentation of cardiac monitoring devices market by Coherent Market Insights comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in global cardiac monitoring devices market over the forecast period, due to increasing prevalence of cardiovascular diseases in the region.

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1272

Key Vendors:

Philips Healthcare, Medtronic, Boston Scientific, Cardiac Science, LifeWatch, CareTaker Medical, Spacelabs, St. Jude Medical, Kohden, CardioNet, and Mortara Instrument.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Visit our news Website: https://www.coherenttimes.org/

Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated with the help of appropriate medication. This has led to intensification of efforts for development of effective and efficient pulmonary drugs and medications. Some of the pulmonary drugs are administered with the help of devices called nebulizers or inhalers.

Click To Continue Reading on Pulmonary Drugs Market

Increasing incidence of Chronic Obstructive Pulmonary Disease (COPD) is directly proportional to the tobacco smoking and exposure. According to the World Health Organization (WHO) 2016, tobacco smoking is the primary cause of COPD leading to around 90% of COPD cases. The irreversible damages caused due to smoke leads to adoption of lifestyle adjustments and medical treatments that includes consumption of bronchodilators, inhaled glucocorticoids, inhaled steroids, and other pulmonary drugs to relieve the disease symptoms, thereby propelling demand for pulmonary drugs. Tobacco is major cause of death and illness across the world. The number of smokers is consistent globally and does not have a drop since a past few years. Smokers are highly susceptible to respiratory diseases such as COPD and asthma.

For instance, according to the Centers of Disease Control and Prevention (CDC) the average rate of smokers in 2012 was 1 in 5 people, which was reported to be constant in the Burden of Tobacco use in the U.S. released in 2015. North America dominates the global pulmonary drugs market, owing to the increasing prescriptions of Inhaled corticosteroids (ICS) and Long-acting beta-agonists (LABA) combinational products. According to Ontario Drug Policy Research Network, 2015, ICS+LABA combination products are the second-most commonly prescribed inhaled respiratory medications for all indications in Canada, with 1.1 million prescriptions dispensed in the fourth quarter of 2013, whereas, short-acting beta-agonists (e.g., salbutamol) are the most frequently prescribed inhaled respiratory medications in Canada with 1.8 million prescriptions dispensed in the same time period.

The government and non-government initiatives help patients to fight the diseases by providing sufficient medical care and education regarding the benefits of preventive measures as well as appropriate medications to curb the life threatening diseases such as COPD. For instance, in 2016, according to the World Health Organization (WHO), more than 90% of deaths were reported due to COPD in low and middle-income economies.

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1285

Key Vendors:

Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZenca Plc., GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi farmaceutici S.p.A., Zambon Company S.p.A., Alaxia SAS, and Merck Sharp & Dohme Limited.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Visit our news Website: https://www.coherenttimes.org/

Tubeless insulin pump is a portable pump, which is effective in controlling blood glucose level. Advancements in technologies of insulin pumps, which reduce the need for daily insulin injection doses is expected to boost growth of the tubeless insulin pump market over the forecast period. Omnipod, by Insulet Corporation is expected to drive the growth of insulin pumps in near future. Omnipod is a novel tubeless insulin pump, which displays blood glucose levels, schedules insulin delivery, and calculates optimal insulin dosage based on food database. Furthermore, Insulet Corporation has recently added additional features such as touchscreen and Bluetooth to Omnipod Dash system. Portability offered by these devices permits easy attachment and placements of the device on clothing or desired body parts, which is expected to drive growth of the tubeless insulin pump market.

Click To Continue Reading on Tubeless Insulin Pump Market

Increasing funding by the government for studying various diseases including diabetes is also expected to fuel growth of the tubeless insulin pump market. For instance, in 2013, National Institute of Diabetes and Digestive and Kidney Disease (NIDDK) funded several important studies on different types of artificial pancreas devices to help patients suffering from type 1 and type 2 diabetes and gestational diabetes. Insulin pumps have gained traction, owing to the rapid acting mechanism offering instant insulin delivery, user friendly interface, and flexible insulin delivery, which is expected to fuel growth of the tubeless insulin pump market over the forecast period.

On the basis of geography, North America is expected to dominate the tubeless insulin pump market, followed by Europe, owing to high adoption rate for new technology and continuous government initiatives to create awareness regarding diabetes.

Increasing prevalence of diabetes due to obesity and increasing geriatric population is driving demand for tubeless insulin pump market. According to the World Health Organization, 2016, an estimated 422 million adults were suffering from diabetes globally. New technologies incorporated into tubeless insulin pump devices is leading to increasing demand for insulin pump devices worldwide. Market players are focused on developing new technologies in tubeless insulin pump devices, which can be used at home with ease and with accurate results, this in turn is expected to boost overall market growth during the forecast period. For instance, in 2016, in the U.K., Medtrum Technologies, Inc. launched S6 Easysense Disposable CGM System, which provides interstitial glucose levels in every two minutes and P6 Tubeless Patch Pump, which is ideal for type 2 diabetes management and gestational diabetes. It also allows monitoring of data using mobile app. However, high long-term cost associated with the use of tubeless insulin pump hampers the market growth. Compliance to therapy reduces over the time, owing to significant cost associated with daily use.

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1298

Key Vendors:

Medtronic Plc., Medtrum Technologies, Inc., Tandem Diabetes Care, Insulet Corporation, and Animas Corporation.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Visit our news Website: https://www.coherenttimes.org/

Multiple sclerosis (MS) is a disabling autoimmune disease affecting the brain and the spinal cord, eventually causing nerve deterioration or permanent damage. The types of MS include relapsing-remitting MS (RRMS), primary progressive MS (PPMS) and secondary progressive MS (SPMS). RPMS is the most common type characterized by defined attacks with increasing neurological symptoms, PPMS is the rare form characterized by gradual progression of disease, whereas SPMS is commonly identified in people living with relapsed-remitting MS. The most common symptoms of the disease include partial or complete vision loss, prolonged vision loss, lack of coordination and slurred speech.

Click To Continue Reading on Multiple Sclerosis Therapeutics Market

A combination of genetic and environmental factors is responsible for the occurrence of the condition. According to a study by International Progressive Alliance, 2013, MS is two to three times more common in women than in men, suggesting that hormones play a significant role in determining susceptibility to the disease.

Multiple sclerosis is a widespread disabling neurological condition, mostly diagnosed in people in the age group 20–50 years. According to the Multiple Sclerosis Foundation, 2017, this autoimmune condition affects 2.5 million people with the global incidence of around 7 cases per 100,000 people per year. The study also states that prevalence rates varies between ethnic and geographical latitudes, ranging from 50 to 120 people per 100,000 population. North America dominates the multiple sclerosis therapeutics market owing to the high prevalence of the condition and the rising economic burden of the disease leading to the adoption of novel therapeutics.

According to the Multiple Sclerosis Foundation, 2015, an estimated 400,000 people live with the disease in U.S., and about 200 new cases are diagnosed every week. According to a survey by Healthline Media, 2015, multiple sclerosis ranks second after congestive heart failure with direct and indirect health care costs ranging from US$ 8,528 to US$ 54,244 per patient per year. Higher therapy cost is restraining the growth of the multiple sclerosis therapeutics market.

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1310

Key Vendors:

Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Bayer AG, Pfizer, Inc., Biogen Idec, Merck & Co., Inc., and AbbVie, Inc.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Visit our news Website: https://www.coherenttimes.org/

Biosimilar is a biological product that resembles a reference product and is not difference from the already approved reference product. These are relatively cheaper than branded or approved products. Several biologics for oncology have already lost their patents, and some are in its period of expiry. As more products are expected to lose patents, biosimilar is expected to gain popularity. Leading generic players such as Mylan N.V., Teva Pharmaceutical Industries Ltd, Allergan Plc, Sandoz (a Novartis International AG’s division) are expected to capitalize on these patent expiries and may establish themselves as dominating players in oncology biosimilars market.

Click To Continue Reading on Oncology Biosimilars Market

There was about a decade gap in approval of first biosimilars in two key markets, Europe and the U.S. First biosimilar was approved in 2006 in Europe, however, in the U.S. first product was approved in 2015. But since approving the first biosimilar, the FDA has approved five products in 2017. Out of these five biosimilars, two were approved for oncology. First, oncology biosimilar Mvasi (bevacizumab-awwb) received approval in September 2017, and second one, Ogivri (trastuzumab) was approved in December 2017. In Europe, both of the products have been approved, and Mvasi received approval from European Commission in January 2018.

Moreover, there are number of biosimilar application pending in the U.S. and Europe. For Herceptin (trastuzumab) alone, there are around four application pending in the FDA. These four application are from Amgen and Allergan, Celltrion and Teva, Pfizer, and Samsung Bioepis. Recent approval of products, and potential approval in next few years is expected to boost the market growth over the forecast period.

On the basis of region, oncology biosimilars market by Coherent Market Insights is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to be the dominant market over the forecast period. U.S. FDA approved first biosimilar in 2015, almost a decade later than first biosimilar approval in Europe. However, since 2015, the number of approved products has increased rapidly. This is expected to be factor for growth of the market in North America. Moreover, currently there are number of products in pipeline, which may receive approval from the FDA over the forecast period. For instance, Pfizer Inc. — a U.S.-based company — has three biosimilar products (i.e. PF-05280014, PF-05280586 and PF-06439535) for oncology in Phase 3.

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1305

Key Vendors:

Amgen Inc., Allergan, Plc, Mylan N.V., Samsung Bioepis Co., Ltd., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Celltrion Healthcare, Novartis International AG, Biogen Idec, Inc., and Biocon Limited.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Visit our news Website: https://www.coherenttimes.org/

Image guided therapy or image guided interventions help surgeons by navigating the devices inside the body of patients and provides a three dimensional image of the targeted area, making the surgery safer and less invasive. The constant flow of information enables surgeons to plan for surgery, make minute adjustments to treat across various therapeutic areas, including cardiac, vascular, endovascular, pain, trauma, urology, orthopedics, spine, and neurology. Image guided therapy devices also can be potentially used in the treatment of hypertension through renal denervation.

Click To Continue Reading on Image Guided Therapy System Market

All these therapeutic areas rely on powerful imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), fixed interventional X-ray, and mobile C-arms. Each modality has advantages and limitations and differs according to its mode of operation, level of complexity, and price point. As the fields of minimally-invasive interventions, interventional imaging, and image-guided surgery (IGS) continue to mature, the advancements in integration of image guided therapy system market with therapeutic modalities in real time is expected to lead to major growth over the forecast period.

Image guided therapy systems provides doctors and technicians with access to patient database records and accordingly develop exact detailed surgical plan or the optimal path to the targeted area.  In addition, ultrasound recording during surgery makes the image guided therapy safer and helps the surgeon to operate on the targeted area avoiding any critical injury to the nearby parts of the area. Various hospitals are focusing on installing image guided system to offer wide range of interventional procedures to patients.

For instance, in November, 2017, UnityPoint Health, a network of hospitals, clinics and home care services in Iowa, Illinois, U.S. and Wisconsin installed Infinix-i-4-D CT (computed tomography) system, a product by Toshiba Medical which offers fast, safe and accurate interventional radiology (IR) and oncology procedures, such as tumor therapy, embolization, arterial interventions, dialysis and stent placement. These rising demand among the hospitals expected to fuel the growth of the image guided therapy system market.

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1315

Key Vendors:

General Electric Company, Toshiba Medical Systems, Siemens AG, Medtronic plc, Brain lab AG, Image Guided Therapy, and Ziehm Imaging, Koninklijke Philips N.V., Varian Medical System, Inc.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Visit our news Website: https://www.coherenttimes.org/

​Radiotherapy, also known as radiation therapy, uses ionizing radiations that deliver targeted beams of radiation to kill and destroy cancer cells. The advanced technology used in radiotherapy works by bombarding cancerous cells with radiation to kill them, while minimizing damage to the healthy cells around them. Radiotherapy is the most potent and cost-effective treatment for cancer, and when integrated with advanced technologies such as image guided therapy, leads to enhanced control over tumor and toxicity.

Click To Continue Reading on Radiotherapy Market

Several types of radiotherapies such as external beam radiation therapy, internal beam radiation therapy/ brachytherapy, and systemic radiation therapy, are available to combat various types of cancers prevalent globally. External beam radiation therapy is used to treat various types of cancers, including brain tumors, bladder cancer, and bone cancers. Brachytherapy is often used to treat cancers of the head and neck, breast, cervix, prostate, and eye, while systemic radiation therapy is often used to treat certain types of thyroid cancers using radioactive iodine.

Rising prevalence of oncology diseases such as prostate cancer, lung cancer, and breast cancer, globally is increasing the demand for timely management to reduce mortality associated with such conditions. This in turn, is a major factor augmenting growth of the radiotherapy market. The International Cancer Association, 2014, states that cancer kills more people every year than AIDS, tuberculosis, and malaria combined. This indicated the growing demand for adopting advanced technologies for cancer management.

According to the World Cancer Research Fund Organization, 2015, lung cancer is among the most prevalent cancers worldwide contributing 1.9 million or 13% of the total number of new cases diagnosed in 2012. It further states that breast cancer is the second most common cancer prevalent among women, with 1.7 million new cases diagnosed in 2012. Moreover, increasing prevalence of cancer among children is expected to increase the demand for radiation therapy, as it is a highly recommended therapy due to fewer adverse effects associated with it than chemotherapy to accelerate growth of the market as considering the major adverse effects of chemotherapy. According to the International Union against Cancer (UICC) Report, 2017, around 160,000 children are estimated to be diagnosed with cancer and at least 90,000 children are estimated to die of cancer globally.

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1320

KeyVendors:

Accuray Incorporated, Varian Medical Systems, Inc., Elekta AB, Ion Beam Applications S.A., C.R. Bard, Inc., Isoray Medical, Inc., CIVCO Radiotherapy, Hitachi Ltd., Mevion Medical Systems, Inc., and ProTom International, Inc.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,#3200
Seattle, WA 98154
Tel: +1-206-701-6702Email:sales@coherentmarketinsights.com

Visit our news Website: https://www.coherenttimes.org/

Parenteral are sterile dosage form that are administered through route other than oral route of administration. They are injected into one or more layer of skin and active ingredient directly come in contact with tissue or blood vessel. Large volume parenteral are of two types, small volume parenteral are single or multi dosage preparation with volume 100 ml or less quantity whereas large volume parenteral has volume more than 100 ml. Large volume parenteral comes in bag or bottle for intravenous administration and are used for correction of fluid/electrolyte balance, providing nutrition such as dextrose.

Click To Continue Reading on Large Volume Parenteral Market 

Increasing demand for palliative care worldwide is expected to drive growth of the large volume parenteral market, owing to use of large volume parenteral to provide electrolyte balance and nutritional fluids. According to World Health Organization (WHO), 2017, an estimate of 40 million people need palliative care worldwide. Around 78% among those people, live in low- and middle-income economies and only 14% of people in need of palliative care receives it. Disease which require high palliative care are cardiovascular diseases (38.5%), cancer (34%), chronic respiratory diseases (10.3%), AIDS (5.7%) and diabetes (4.6%), kidney failure, chronic liver disease.

This creates potential opportunity for large volume parenteral market players. Increasing number of surgeries are expected to propel growth for the large volume parenteral market worldwide. For instance, according to World Bank statistics, in 2012, around 4511 surgeries were performed per 1,00,000 population across the globe. As per Lancet Commission for Global Surgery, 2015, an estimate of 143 million unmet surgical need per year, surgical need in turn drives large volume parenteral market as they are essential part of pre and post-operative care.

Regional segmentation of the large volume parental market by Coherent Market Insights consist of North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is expected to dominate the large volume parenteral market, owing to increasing number of hospital admissions and cost associated with such admission (an estimated US$ 1900 in 2013 as per Kaiser Health fact). According to American Hospital Association factsheet 2018, an estimated 35,158,934 hospital admissions were reported in 2017, large volume parenteral is integral part of any admission procedure, as nutrition and electrolyte support is essential in most of the cases.

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1323

Key Vendors:

Baxter International Inc., Teva Pharmaceutical Industries Limited, Kelun Pharmaceutical Inc., BAG Healthcare GmbH, Hospira, Inc., Patheon Inc., Otsuka Pharmaceutical, Wockhardt Ltd., Southwest Pharmaceutical Co. Ltd., and Cook Pharmica LLC.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Visit our news Website: https://www.coherenttimes.org/

Vascular closure devices (VCDs) are medical devices used to achieve vascular hemostasis after the puncture of femoral artery during diagnostic angiography procedures or interventional procedures. VCDs are developed as an alternative of mechanical compression. Although mechanical compression is effective method for treatment of hemostasis, it take a longer time period to effectively achieve hemostasis than vascular closure devices. VCDs has been available in the U.S. since 1995, when St. Jude Medical, Inc. received the approval for VasoSeal device. Since then, number of leading medical devices such as Abbott Laboratories, Medtronic Plc, and Terumo Corporation companies have entered in the market.

Click To Continue Reading on Vascular Closure Device Market

Vascular closure devices are medical devices used in sealing puncture of the femoral artery in patients who have undergone diagnostic angiography procedures or interventional procedures. Vascular closure devices are alternative to manual compression method, manually compression takes longer time, depending on the size of the plastic sheath placed in the artery. Vascular closure devices provide immediate sealing of the femoral artery access site, which is not the case with mechanical or manual compression.

Increasing demand for diagnostic angiography procedures due to increasing prevalence of Coronary heart disease (CHD) is expected to increase demand for vascular closure device in near future. For instance according to the research published in Centers for Disease Control and Prevention (CDC) in 2017, Coronary heart disease (CHD) is one common type of heart disease, which causes about 370,000 deaths in U.S. annually. Furthermore the launch of innovative vascular closure devices in market is also expected create lucrative environment for market growth. For instance in 2014, AccessClosure Inc. launched Mynx Ace vascular closure device at annual scientific session of the American College of Cardiology in Washington, DC. Furthermore, in 2017, Vasorum Ltd. launched Celt ACD second generation vascular closure device in the U.S. market.

Vascular closure device are primarily used for vascular hemostasis after puncture of the femoral artery during angiography. Angiography is an imaging technique used to visualize interior of blood vessels including artery. The technique has been increasingly used for finding out if the arteries are blocked, closed or narrowed. According to research published by World Health Organization (WHO) in 2017, about 17.7 million people died from cardiovascular diseases in 2015, which is about 31% of all global deaths. Among these death around 7.4 million death were due to coronary heart disease and 6.7 million were due to stroke. As the prevalence of the cardiovascular disease is increasing, the demand for angiography, a diagnosis technique, is expected to increase which in turn will lead to growth in global vascular closure devices market.

This market has witnessed few recalls, which has proved to be major restraining factor for market growth. For instance, in 2017 Abbott Vascular recall 66 lots of the StarClose SE Vascular system due to difficulty in deploying the clip.

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1330

Key Vendors:

Abbott Laboratories, Medtronic Plc., Transluminal Technologies LLC, Cardinal Health, Inc., Cardiva Medical, Inc., Terumo Corporation, Essential Medical, Inc., Vascular Closure Systems, Inc., Vivasure Medical Ltd., Vasorum Ltd. , and Morris Innovative Inc.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Visit our news Website: https://www.coherenttimes.org/

Patient positioning devices are used in various surgical and diagnostics procedures for patient's safety and surgeon's ease of access to the area of operation. The choice of surgical positioning devices majorly depends on the type of surgery to be performed. Positioning patients correctly in the operating room is important on order to provide the best care possible and preventing problems such as nerve damage and pressure ulcers. Increasing prevalence of chronic diseases and technological advancements in the patient positioning equipment are expected to drive growth of global patient positioning devices market.

Click To Continue Reading on Patient Positioning Devices Market

Increasing number of surgeries due to high prevalence of chronic diseases is expected to be a major factor driving growth of global patient positioning devices market during the forecast period. According to World Health Organization (WHO) report, around 23.6 million new cases of cancer are projected to be reported worldwide by 2030. High prevalence of chronic diseases such as cancer and kidney disorders demand for increasing therapeutic and diagnostic procedures including radiation therapy. For instance, according to National Kidney Foundation data 2015, 10% of the population is affected by chronic kidney disease worldwide.

According to study published by National Center for Biotechnology Information (NCBI), in 2014, robotic assisted surgeries showed 6.6% injury rate, signifying risk associated with robotic surgery. Positioning injuries are identified in open surgery, however laparoscopic surgery experience increased risk. However, pelvic surgeries, both laparoscopic and open can experience higher neurologic damage due to autonomic nerve disruption from surgical dissection, improper lithotomy positioning, and incorrect placement of retractors. Though incidence rates for injuries are low it offers a great market opportunity for developing equipment aimed at eliminating these injuries.

Latest surgical procedures such as minimally invasive and robotic surgery face various challenges in positioning the patient safely and providing adequate access to the surgical site. Increasing number of robotic surgeries requiring more specific positioners has spurred the patient positioning devices market growth. For instance, D.A. Surgical TrenGuard is one of the most efficient and effective patient positioning system in the market. Sports medicine utilizes a wide range of patient positioning equipment including distraction devices for arthroscopic procedures and small-incisions. For instance, knee surgery, one of the most frequent sports-related surgery, relies majorly on distraction devices compared to manual manipulation of the limb.

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1353

Key Vendors:

Alvo, Civco Radiotherapy, C-Rad, Dexta, Eschmann Equipment, Elekta AB, Getinge AB, GE Healthcare, Hill-Rom, Inc., Innovative Medical Products, Inc., Leoni AG, Merivaara Corp., Medifa-Hesse GmbH & Co. Kg, Mizuho OSI, Opt Surgisystems S.R.L, Mediland Enterprise Corporation, Schuremed, Smith & Nephew PLC, Span America Medical Systems, Inc., Steris PLC, Stryker Corporation, Skytron, and Xodus Medical Inc.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Visit our news Website: https://www.coherenttimes.org/